Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIANA-NEXT: Dotinurad vs febuxostat in hyperuricemia with hypertension
jRCTs021240066Active, not recruiting
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in hyperuricemia and hypertension (HTN) comparing Dotinurad with Febuxostat (2 arms). Primary endpoint: Change in CAVI at 24 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
dotinuradfebuxostat
03
Conditions
hyperuricemiahypertension (HTN)
Beyond the preview
Go deeper on jRCTs021240066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021240066.